Mai K T, Landry D C, Thomas J, Yazdi H M, Perkins D G, Odell P F
Department of Laboratory Medicine, Ottawa Hospital, Ontario, Canada.
Tumori. 2001 May-Jun;87(3):166-72. doi: 10.1177/030089160108700311.
Activation of Ret oncogenes, particularly Ret/PTC, has been identified in papillary thyroid carcinoma (PTC). The purpose of this study was to investigate the immunostaining pattern of Ret oncogene protein in PTC and nodular non-PTC lesions with a fine chromatin pattern.
Ninety-three PTC and 139 nodular non-PTC lesions were microscopically reviewed to identify the nuclear changes of "limited nuclear features of PTC" (focal nuclear grooves, nuclear inclusions or optically clear nuclei) and areas of infiltrating carcinoma (IC) and were submitted for immunostaining with Ret oncogene protein antiserum.
Immunoreactivity for Ret protein ranged from negative in follicular adenoma (FA) with a coarse chromatin pattern, to negative or weak reactivity in FA with a fine chromatin pattern, to strong reactivity in PTC with areas of infiltrating carcinoma (IC). In FA with fine chromatin, FA and follicular carcinoma (FC) containing an admixture of areas of coarse and fine chromatin, areas with nuclear changes with "limited nuclear features of PTC" displayed varying degrees of immunoreactivity. The intensity of immunostaining varied with the degree of nuclear change. The noninvasive component of PTC with IC usually showed more extensive and stronger reactivity than PTC without IC. PTCs with and without IC were associated with a rate of lymph node metastasis of 48% and 3%, respectively.
The expression of Ret oncogenes (Ret/PTC, other unknown variants or wild type) is focally or extensively present in all PTC with IC. The degree of immunoreactivity is likely to be proportional to the potential for lymph node metastasis of PTC. In the context of this study and due to the specificity of Ret oncogenes, it is likely that nodular non-PTC lesions with a fine chromatin pattern and focal positive reactivity for Ret oncogene represent PTC-related lesions.
在甲状腺乳头状癌(PTC)中已发现Ret癌基因的激活,尤其是Ret/PTC。本研究的目的是调查Ret癌基因蛋白在PTC以及具有精细染色质模式的结节性非PTC病变中的免疫染色模式。
对93例PTC和139例结节性非PTC病变进行显微镜检查,以确定“PTC的有限核特征”(局灶性核沟、核内包涵体或透明核)的核变化以及浸润癌(IC)区域,并提交用Ret癌基因蛋白抗血清进行免疫染色。
Ret蛋白的免疫反应性范围从具有粗糙染色质模式的滤泡性腺瘤(FA)中的阴性,到具有精细染色质模式的FA中的阴性或弱反应性,再到具有浸润癌(IC)区域的PTC中的强反应性。在具有精细染色质的FA、含有粗糙和精细染色质区域混合的FA和滤泡癌(FC)中,具有“PTC的有限核特征”核变化的区域显示出不同程度的免疫反应性。免疫染色强度随核变化程度而变化。伴有IC的PTC的非侵袭性成分通常比不伴有IC的PTC显示出更广泛和更强的反应性。伴有和不伴有IC的PTC的淋巴结转移率分别为48%和3%。
Ret癌基因(Ret/PTC、其他未知变体或野生型)的表达在所有伴有IC的PTC中呈局灶性或广泛存在。免疫反应性程度可能与PTC的淋巴结转移潜力成正比。在本研究的背景下,由于Ret癌基因的特异性,具有精细染色质模式且对Ret癌基因呈局灶性阳性反应的结节性非PTC病变可能代表与PTC相关的病变。